Welcome to our dedicated page for Alterity Therapeutics SEC filings (Ticker: ATHE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Alterity Therapeutics Limited (ATHE) provides access to the company’s disclosures as a foreign private issuer listed on NASDAQ. Alterity files reports under the Securities Exchange Act of 1934, including its annual report on Form 20‑F and current reports on Form 6‑K, and describes itself in these documents as a development stage enterprise focused on neurodegenerative diseases.
For investors following this clinical stage biotechnology company, Form 6‑K filings are particularly important. They often include material that has been released to the Australian Securities Exchange, such as quarterly Appendix 4C cash flow reports, clinical trial updates for ATH434 in Multiple System Atrophy (MSA), regulatory designations like U.S. FDA Fast Track status, and information on capital raisings or strategic placements. Other 6‑K submissions may contain meeting results, presentations to shareholders, and notices related to board or director changes.
Alterity’s Form 20‑F annual report (when filed) typically consolidates information on its business overview, risk factors, research and development focus on Parkinsonian and other neurodegenerative disorders, and its status as a clinical stage company. These filings complement the company’s scientific and clinical communications by outlining its segment focus on research and development and its listing arrangements on the Australian Securities Exchange and NASDAQ.
On Stock Titan, this page surfaces Alterity’s SEC filings as they are made available from EDGAR and pairs them with AI‑powered summaries to help readers interpret technical language. Users can quickly see the purpose of each 6‑K or 20‑F, identify items related to ATH434 clinical data, regulatory interactions, cash flow disclosures, and corporate governance, and then drill into the full text for detailed review.
Alterity Therapeutics Limited has issued 18,000,000 new unlisted options under its employee incentive scheme. These options have an exercise price of AUD 0.008 and expire on 9 January 2031, and on exercise will convert into ordinary fully paid ATH shares.
The options form a new unquoted security class that is not intended to be quoted on ASX, and all options in this class rank equally from the issue date of 15 January 2026. The filing also notes that this report is incorporated by reference into Alterity’s existing Form S-8 and Form F-3 registration statements.
Alterity Therapeutics Limited has reported the grant of 43,500,000 unlisted options under its employee incentive scheme. These options have an exercise price of USD 0.0057 and expire on 13 January 2031, and are in a new unquoted class that will convert into ordinary fully paid ATH shares if exercised. None of the options were issued to key management personnel, and the issue was made under exception 13 in ASX Listing Rule 7.2, meaning separate security holder approval was not required. Following this grant, Alterity continues to have over 10.8 billion ordinary shares quoted on ASX along with several other series of quoted and unquoted options on issue.
Alterity Therapeutics is a late clinical stage biopharmaceutical company developing ATH434, an oral small molecule designed to chaperone excess labile iron in the brain, aiming to reduce α‑synuclein aggregation and oxidative injury in neurodegenerative diseases. The company reported positive Phase 2 results in multiple system atrophy (MSA), a rapidly progressive Parkinsonian disorder with no approved treatment, showing clinically meaningful benefits on the modified Unified MSA Rating Scale, global severity ratings, orthostatic hypotension symptoms and wearable movement metrics, with a favorable safety profile and MRI evidence of reduced brain iron. An open‑label study in more advanced MSA patients showed efficacy and biomarker effects consistent with the double‑blind trial. Independent commercial research estimated potential worldwide annual peak sales of USD $2.4 billion for ATH434 in MSA, and the company reported a cash balance of A$54.5 million as of 30 September as it prepares for a pivotal Phase 3 program.
Alterity Therapeutics Limited filed a Form 6-K furnishing an Appendix 3Y notice from the ASX that records a change in director interests for David Stamler. The filing shows that 91,392,720 unlisted options expiring on 06 January 2026 with an exercise price of $0.0320 expired and are now recorded as nil.
No ordinary shares or American Depositary Shares were acquired or disposed of, and the value/consideration for the expired options is listed as “NIL.” Stamler continues to hold fully paid ordinary shares, listed options with later expiries, further unlisted options, and 133,333 American Depositary Shares held indirectly through HSBC Custody Nominees. The Form 6-K is also incorporated by reference into several existing Form S-8 and Form F-3 registration statements.
Alterity Therapeutics Limited reports that 91,392,720 unquoted options with ASX code ATHAAD, exercisable at $0.032 and expiring on 6 January 2026, have lapsed without being exercised or converted. No consideration was paid in connection with this expiry.
Following this change, the company’s issued capital on ASX comprises 10,875,416,329 ordinary fully paid shares (ATH), along with quoted options ATHO (option expiring 31 August 2026) totaling 931,232,089 and ATHOA (option expiring 26 February 2027) totaling 1,222,300,911. Various classes of unquoted options remain on issue, while the ATHAAD class now has zero securities outstanding.